The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer: Analysis of a large international cohort of 5,900 patients.
Gargi Dan Basu
Employment or Leadership Position - Caris Life Sciences
Stock Ownership - Caris Life Sciences
Joanne Xiu
Employment or Leadership Position - Caris Life Sciences
David Arguello
Employment or Leadership Position - Caris Life Sciences
Stock Ownership - Caris Life Sciences
Rebecca A. Feldman
Employment or Leadership Position - Caris Life Sciences
Stock Ownership - Caris Life Sciences
Sherri Z. Millis
Employment or Leadership Position - Caris Life Sciences
Ryan P. Bender
Employment or Leadership Position - Caris Life Sciences
Stock Ownership - Caris Life Sciences
Zoran Gatalica
Employment or Leadership Position - Caris Life Sciences
Stock Ownership - Caris Life Sciences
Les Paul
Employment or Leadership Position - Caris Life Sciences
Stock Ownership - Caris Life Sciences
Expert Testimony - AMA CPT editorial board for MGMT methylation New code (U)
Fadi S. Braiteh
Consultant or Advisory Role - Caris Life Sciences
Honoraria - Caris Life Sciences
Research Funding - Caris Life Sciences